Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score

Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score

Bibliographic Details
Main Authors:	M.C. Mir Maresma, M. Marchioni, R. Campi, A. Minervini, M. Kriegmair, M. Heck, F. Porpiglia, S. Van Bruwaene, E. Linares, V. Hevia, M. Musquera, I. Derweesh, F. Ghali, R. Autorino, A. Veccia, E. Roussel, M. Albertsen, N. Pavan, A. Antonellia, C. Palumbo, U. Capitanio, T. Klatte, S. Erdem, J. Rubio-Briones
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320334340

Similar Items

Predictors for perioperative complications in cytoreductive nephrectomy: Analysis of the registry for metastatic RCC (REMARCC)
by: E. Roussel, et al.
Published: (2020-07-01)

Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry
by: M.F. Meagher, et al.
Published: (2020-07-01)

The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: A retrospective analysis of a contemporary series
by: M. Marchioni, et al.
Published: (2020-07-01)

The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: a retrospective analysis of a contemporary series
by: M. Marchioni, et al.
Published: (2020-10-01)

Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy
by: Margaret F. Meagher, et al.
Published: (2024-05-01)

Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 (“Oligometastatic”) and M2 (“Polymetastatic”) subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)
by: Margaret F. Meagher, et al.
Published: (2023-03-01)

Proposal for a two-tier re-classification of stage IV/M1 renal cell carcinoma into M1 (oligometastatic) and M2 (polymetastatic) sub stages
by: M.F. Meagher, et al.
Published: (2020-07-01)

Lymph node dissection is associated with decreased survival and all cause mortality among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma
by: S. Weprin, et al.
Published: (2020-07-01)

Comparative analysis of functional outcomes of open and minimally invasive partial nephrectomy stratified by tumor complexity: A multi-center study
by: F. Ghali, et al.
Published: (2020-07-01)

Clinical, surgical, pathological and follow-up features of kidney cancer in patients with von hippel-lindau syndRoma: novel insights from a large european consortium
by: U. Capitanio, et al.
Published: (2020-10-01)

Clinical, surgical, pathological and follow-up features of kidney cancer in patients with Von Hippel-Lindau syndrome: Novel insights from a large European consortium
by: U. Capitanio, et al.
Published: (2020-07-01)

Robot-assisted partial nephrectomy for completely endophytic renal tumors: A multicenter outcome analysis
by: U. Carbonara, et al.
Published: (2020-10-01)

Transurethral prostate surgery is safe in patients with prostate cancer: Results from a population-based analysis
by: M. Marchioni, et al.
Published: (2020-07-01)

ICG-near infrared guided robot-assisted pyeloplasty in patient with retrocaval ureter
by: Alessandro Veccia, et al.
Published: (2019-09-01)

The role of cytoreductive surgery in multifocal/multicentric glioblastoma
by: D. Dimov, et al.
Published: (2022-01-01)

Cytoreductive interventions in combination with hyperthermic intraperitoneal chemoperfusion in pseudomyxoma
by: A. G. Abdullayev, et al.
Published: (2014-08-01)

The impact of ischemia on chronic kidney disease progression after robotic partial nephrectomy in patients over 75 years old: Results of a multi-institutional collaborative series (ROSULA)
by: U. Anceschi, et al.
Published: (2020-07-01)

Impact of tumor cytoreduction in metastatic prostate cancer
by: Sow Y, et al.
Published: (2019-05-01)

New Paradigms for Cytoreductive Nephrectomy
by: Benjamin J. Lichtbroun, et al.
Published: (2022-05-01)

Cytoreductive Nephrectomy in 2021: Obsolete
by: Luis Meza, et al.
Published: (2022-02-01)

Quaternary and beyond cytoreduction: An updated and expanded analysis
by: Beryl L. Manning-Geist, et al.
Published: (2021-08-01)

Cytoreductive HIPEC-Combined Surgery in Treatment of Advanced Ovarian Cancer
by: M. V. Zabelin, et al.
Published: (2022-06-01)

The role of cytoreduction surgery in advanced ovarian cancer (review)
by: R K Tandelov, et al.
Published: (2018-03-01)

The role of cytoreductive nephrectomy in the contemporary management of metastatic kidney cancer: Predictive factors for surgical complications and oncological survival
by: E. Roussel, et al.
Published: (2020-07-01)

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study
by: Alessio Pecoraro, et al.
Published: (2023-06-01)

Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only.
by: Grégoire Désolneux, et al.
Published: (2015-01-01)

Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease
by: Juan José Segura-Sampedro, et al.
Published: (2020-05-01)

Development of a nomogram to predict achievement of trifecta outcomes after robotic partial nephrectomy for cT1-2 renal tumors
by: A. Brassetti, et al.
Published: (2020-07-01)

Development of a nomogram to predict achievement of trifecta outcomes after robotic partial nephrectomy for cT1-2 renal tumors
by: A. Brassetti, et al.
Published: (2020-10-01)

Combined assessment of long-term functional and oncologic outcomes after robot-assisted partial nephrectomy: The ROMe’s score
by: A. Brassetti, et al.
Published: (2020-07-01)

Describing long-term functional and oncologic outcomes of robot-assisted partial nephrectomy: the roma score
by: A. Brassetti, et al.
Published: (2020-10-01)

Retroperitoneal Robot-assisted Partial Nephrectomy: A Systematic Review and Pooled Analysis of Comparative Outcomes
by: Umberto Carbonara, et al.
Published: (2022-06-01)

Safety profile of robotic vs. laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) collaborative group
by: A. Veccia, et al.
Published: (2020-07-01)

Robotic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) collaborative group
by: A. Veccia, et al.
Published: (2020-07-01)

Cytoreductive Nephrectomy: Still Necessary in 2021
by: Arnaud Méjean, et al.
Published: (2022-02-01)

Cytoreductive nephrectomy in the current treatment algorithm
by: Teele Kuusk, et al.
Published: (2019-09-01)

Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature
by: Michele Marchioni, et al.
Published: (2022-07-01)

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression
by: Krishan R. Jethwa, et al.
Published: (2016-11-01)

The importance of sign and symptoms assessment in patients with metastatic renal cell carcinoma: implications for cytoreductive nephrectomy
by: A. Larcher, et al.
Published: (2020-10-01)

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
by: G. N. A. Winarno, et al.
Published: (2020-07-01)